Registry of Patients With Hematologic Disease and COVID-19 in Russia
CHRONOS19
Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)
1 other identifier
observational
666
1 country
15
Brief Summary
This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2020
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 8, 2020
CompletedFirst Posted
Study publicly available on registry
June 9, 2020
CompletedStudy Start
First participant enrolled
June 22, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 22, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 18, 2022
CompletedJanuary 26, 2023
January 1, 2022
1.2 years
June 8, 2020
January 25, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
30-day all-cause mortality
Rate of death from any cause
30 day
Secondary Outcomes (6)
COVID-19 complications
30 day
ICU admission
30 day
Mechanical ventilation / O2 requirement
30 day
Relapse or progression of hematologic disease
30 day, 90 day and 180 day
Overall survival
30 day, 90 day and 180 day
- +1 more secondary outcomes
Interventions
Non-interventional study
Eligibility Criteria
Patients with hematologic disease (both malignant and non-malignant) infected with SARS-CoV-2
You may qualify if:
- Age 18 or older
- Any previously or currently diagnosed hematologic disease
- Laboratory confirmed or suspected (based on clinical symptoms and/or CT) COVID-19
- Known outcome of COVID-19 in case of retrospective data input (protocol allows retrospective data input for patients who were prospectively followed in local centers)
You may not qualify if:
- Loss of follow-up within 30 days after COVID-19 diagnosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Research Center for Hematology, Russialead
- Foundation for Cancer Research Support (RakFond)collaborator
- Enrollme.ru, LLCcollaborator
Study Sites (15)
Republican Clinical Hospital of Tatarstan
Kazan', Russia
City Hospital n.a. V.V. Veresaev
Moscow, Russia
Clinical Hospital n.a. S.P. Botkin
Moscow, Russia
N.V. Sklifosovsky Emergency Institute
Moscow, Russia
National Research Center for Hematology
Moscow, Russia
Regional Clinical Hospital N.A. Semashko
Nizhny Novgorod, Russia
Regional Hospital
Novosibirsk, Russia
Regional Clinical Hospital
Omsk, Russia
RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University
Saint Petersburg, 197022, Russia
Republican Clinical Hospital No4
Saransk, Russia
Republic Clinical Hospital n.a. N.A. Semashko
Ulan-Ude, Russia
Regional Clinical Hospital
Vladimir, Russia
Regional Clinical Hospital No2
Vladivostok, Russia
Regional Clinical Hospital
Yaroslavl, Russia
Regional Clinical Hospital No1
Yekaterinburg, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Elena Parovichnikova
National Research Center for Hematology
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2020
First Posted
June 9, 2020
Study Start
June 22, 2020
Primary Completion
August 22, 2021
Study Completion
January 18, 2022
Last Updated
January 26, 2023
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will not share